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A large body of evidence supports the Amyloid β (Aβ) 
cascade hypothesis underlying neurodegeneration in 
Alzheimer’s disease (AD).  Although the mechanism by 
which Aβ induces neuronal dysfunction and death is 
still matter of debate, in the last two decades several 
groups have generated compelling evidence supporting 
a role of Amyloid β Precursor Protein (APP) as a bona 
fide receptor for Aβ that can trigger neurodegeneration 
[1].  
Our initial discovery that APP binds Aβ fibrils and 
mediates its neurotoxic effect on neuronal cultures [2] 
was subsequently extended by reports showing that 
harmful effects of diverse Aβ-assemblies are APP-
dependent. Recently, Wang and collaborators reported 
that both, Aβ-derived diffusible ligands (ADDL) and 
Aβ oligomers extracted from human AD brain, impaired 
long-term potentiation in an APP-dependent manner 
[3]. Furthermore, another group showed that intracranial 
infusion of Aβ oligomers impaired associative fear and 
spatial learning in WT mice but had no amnesic effect 
in APP-KO mice [4].  
How APP mediates toxicity of Aβ-assemblies? Working 
in hippocampal neurons in culture we provided initial 
evidence that APP is a receptor for Aβ fibrils that 
mediates toxicity by activating Go signaling [5] There-
after, Fogel and collaborators extended this observation 
showing that, in cultured neurons naturally secreted Aβ 
binds to APP, activating a Go protein signaling cascade 
that modulates presynaptic glutamate release in 
physiological conditions [6]. Interestingly, these authors 
also observed that preventing Aβ degradation by 
neprilysine inhibition further enhanced APP-Go 
signaling and glutamate release. All these observations 
strongly suggest that accumulation of Aβ in AD brain 
might trigger pathological activation of APP-Go 
signaling, leading to neuronal dysfunction. We recently 
published data further supporting this hypothesis [6]. 
We found that APP-dependent toxicity of Aβ fibrils is 
mediated by Gβγ complex signaling, and we also 
identified p38MAPK as a downstream target of Gβγ 
complex. Furthermore, we found that Aβ fibrils en-
hanced the interaction of APP and Go protein in 
dystrophic neurites of mature hippocampal cultures, 
suggesting that Aβ deposition triggers sustained APP-
Go signaling. Consistent with this interpretation, we 
observed that Gallein, a specific inhibitor of Gβγ sig-
naling, protected  mature  hippocampal  cultures  against 








Aβ-induced dystrophy and degeneration. The protective 
effect of Gallein was robust and effective against 
toxicity induced by different Aβ aggregates, suggesting 
that sustained over-activation of APP and Go/Gβγ 
complex signaling is a common pathological pathway 
for diverse toxic Aβ species.  In addition, we also found 
that the protective effect of Gallein in vitro extended to 
several pathologic markers characteristic of AD, in-
cluding somatodendritic localization of abnormally 
phosphorylated tau, dystrophic degeneration of axons 
and dendrites, loss of synapses and neuronal cell death 
[7].  
Mechanistically, Gallein prevented Aβ-induced 
phosphorylation of p38-MAPK in mature neurons, 
indicating that this kinase is a downstream target of Gβγ 
complex. In fact, SB203580, a specific inhibitor of p38-
MAPK, effectively prevented Aβ-induced redistribution 
of phosphorylated tau to the somatodendritic com-
partment.  However, SB203580 exerted a partial 
protection against Aβ-induced dendritic dystrophy, sug-
gesting that, besides p38-MAPK, other effectors 
downstream Gβγ might participate in dendritic dyst-
rophy. Regardless of this, Gallein prevented the loss of 
synaptophysin/PSD95 puncta in Aβ-treated cultures, 
underscoring Gβγ inhibition as an effective intervention 
to preserve synapses. To test the role of APP-Go/Gβγ 
signaling in vivo we utilized the 3xTg-AD mice, which 
develop Aβ-related deficits in synaptic plasticity and 
memory performance. By using the novel object 
recognition task we found that intrahippocampal 
injections of Gallein were effective in reversing memo-
ry impairment. This behavioral observation together 
with our in vitro data indicate that sustained activation 
of APP/Go protein Gβγ-complex signaling triggered by 
toxic Aβ assemblies might play a critical role in neuro-
nal dysfunction and degeneration in AD.  
Compelling evidence indicates that Aβ peptides activate 
APP/Go signaling in both, physiologic and pathologic 
conditions. Activation of APP/Go signaling by Aβ 
monomers/dimmers is physiologically regulated by 
degradation and clearance of the peptide. However, 
pathologic species of Aβ (oligomers/fibrils) that are 
resistant to clearance induce persistent APP/Go 
signaling that causes neuronal dysfunction and dege-
neration. This perspective on the physio-pathological 
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